Previous Close | 5.65 |
Open | 5.00 |
Bid | 3.90 |
Ask | 7.50 |
Strike | 19.00 |
Expire Date | 2024-06-21 |
Day's Range | 5.00 - 5.65 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET in New York City. A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will report data highlighting the robust, closed and automated manufacturing process for BEAM-101, as deployed in the BEACON Phase 1/2 clinical trial, in a poster presentation at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Madrid, Spain on Jun
In this article, we will take a look at the 15 best ARK stocks to buy now. To see more such companies, go directly to 5 Best ARK Stocks To Buy Now. Cathie Wood is one of the most polarizing, and prominent figures on Wall Street. With over three decades of experience in the financial sector, […]